Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,271 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "ALL" Condition: Leukemia Clear all
Recruiting No phase listed Observational

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

NCT05724121
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia, Mantle Cell Lymphoma, Sudden Cardiac Death, Cardiac Arrhythmias, Hematologic Malignancies
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 110 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

NCT00374933
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI, "Prophylactic" delayed ADLI, "Prophylactic" delayed activated donor lymphocyte infusion
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Sep 11, 2026, 10:02 AM EDT
Not listed Phase 1 Interventional

PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)

NCT03709914
View directory record Official record
Conditions
Pediatric ALL
Interventions
ZTI-01 100 mg/kg, ZTI-01 75 mg/kg
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
Up to 11 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
5
States / cities
Orange, California • San Diego, California • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 11, 2026, 10:02 AM EDT
Not yet recruiting Not applicable Interventional

Prevention of Oral Mucositis in Adults in With Hematologic Malignancy

NCT07809984
View directory record Official record
Conditions
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Oral Mucositis
Interventions
Aloe Vera Mouthwash, Standard of Care
Dietary Supplement · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Oak Lawn, Illinois • Park Ridge, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

NCT02665143
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia
Interventions
Nintedanib and AML induction
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
New Haven, Connecticut • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL

NCT01496976
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
High Dose Methylprednisolone (HDMP), Ofatumumab, Lenalidomide
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 11, 2026, 10:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia)

NCT04785989
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
[U-13C]glucose, [13C5]glutamine
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 11, 2026, 10:02 AM EDT
Completed No phase listed Observational

C-Reactive Protein as a Predictor of Stem Cell Transplant Complications

NCT00179868
View directory record Official record
Conditions
Cancer, Leukemia, Stem Cell Transplantation
Interventions
C-Reactive Protein levels
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
6 Months to 20 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 11, 2026, 10:02 AM EDT
Terminated Not applicable Interventional

Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

NCT02226497
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Health Telemonitoring, Quality-of-Life Assessment, Questionnaire Administration, Supportive Care
Device · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Sep 11, 2026, 10:02 AM EDT
Terminated Phase 1 Interventional

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

NCT00105313
View directory record Official record
Conditions
Lymphoma, Leukemia, Cancer
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2007 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 3 Interventional

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00024440
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, oblimersen sodium, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Berkeley Heights, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 5, 2014 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

NCT05564650
View directory record Official record
Conditions
Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome
Interventions
Navitoclax, Venetoclax, Decitabine, Bone Marrow Biopsy, Biospecimen Collection, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Biological · Drug · Procedure + 1 more
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

NCT01772420
View directory record Official record
Conditions
Adult Myelodysplastic Syndrome, Anemia, Chronic Myelomonocytic Leukemia
Interventions
Eltrombopag Olamine, Laboratory Biomarker Analysis, Lenalidomide
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
2
States / cities
Kansas City, Kansas • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 11, 2026, 10:02 AM EDT
Active, not recruiting Phase 1 Interventional

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT06291220
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Obinutuzumab, ABBV-453
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Billings, Montana + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 11, 2026, 10:02 AM EDT
Terminated Phase 2 Interventional Results available

Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01846624
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML) With Multilineage Dysplasia Following Myelodysplastic Syndrome, in Adults, AML (Adult) With 11q23 (MLL) Abnormalities, AML (Adult) With Del (5q), AML (Adult) With Inv (16) (p13; q22), AML (Adult) With t (16;16) (p13; q22), AML (Adult) With t (8; 21) (q22; q22), Secondary AML (Adult), Untreated AML (Adult)
Interventions
Decitabine, Midostaurin
Drug
Lead sponsor
David Iberri
Other
Eligibility
60 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00054236
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 4 Interventional

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

NCT01742299
View directory record Official record
Conditions
GIST and CML
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
0 Years to 100 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

NCT00345826
View directory record Official record
Conditions
Leukemia
Interventions
dasatinib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation

NCT00737516
View directory record Official record
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
HPC, Cord Blood
Biological
Lead sponsor
National Marrow Donor Program
Other
Eligibility
Female only
Enrollment
3,621 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2011
U.S. locations
19
States / cities
Covina, California • Orange, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 1 Interventional

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

NCT00003368
View directory record Official record
Conditions
Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
45
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 11, 2026, 10:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

NCT04435691
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Azacitidine, Magrolimab, Venetoclax
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

NCT02281084
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Oral Azacitidine, Durvalumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
23
States / cities
New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

NCT00866749
View directory record Official record
Conditions
Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Methotrexate, Doxorubicin, Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 11, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Exercise Training to Promote Resilience to Chronic Lymphocytic Leukemia

NCT04950452
View directory record Official record
Conditions
Aging, Chronic Lymphocytic Leukemia
Interventions
Exercise Training
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 11, 2026, 10:02 AM EDT